Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition

19 Aug 2021

Abstract excerpt

Abstract Monotherapy with PARP inhibitors is effective for the subset of castrate-resistant prostate cancer (CRPC) with defects in homologous recombination (HR) DNA repair. New treatments are required for the remaining tumors, and an emerging strategy is to combine PARP inhibitors with other therapies that induce DNA damage. Here we tested whether PARP inhibitors are effective for HR-proficient CRPC, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34413130
DOI: 10.1158/1535-7163.mct-20-0932

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP InhibitionPMID 34413130Read ↗

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate CancerSemantic proximity Read ↗

PARP inhibitors for homologous recombination-deficient prostate cancer.Semantic proximity Read ↗

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.Semantic proximity Read ↗

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate CancerSemantic proximity Read ↗

Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerSemantic proximity Read ↗

Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?Semantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read ↗

Preclinical patient‐derived modeling of castration‐resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient diseaseSemantic proximity Read ↗

Targeting DNA RepairSemantic proximity Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging TrendsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.